Bacteriophage virus-like particle vaccines against dengue virus non-structural protein 1

抗登革热病毒非结构蛋白1的噬菌体病毒样颗粒疫苗

• 批准号: 10056169
• 负责人: Kathryn M. Frietze
• 金额: $ 18.94万
• 依托单位: UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-21 至 2022-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10056169
• 关键词: Aedes; Antibodies; Antibody Response; Antibody titer measurement; Antigens; Antiviral Agents; Bacteriophages; Binding; Biological Assay; Blood; Blood Platelets; Blood Vessels; Caring; Cells; Characteristics; Dangerousness; Data; Dengue; Dengue Infection; Dengue Vaccine; Dengue Virus; Developing Countries; Development; Disease; Endothelial Cells; Engineering; Epitopes; Extravasation; Flavivirus; Goals; Human; Immune; Immunization; Immunize; In Vitro; Individual; Infection; Knowledge; Lead; Length; Mediating; Mosquito Control; Mus; Nonstructural Protein; Pathogenesis; Pathogenicity; Peptides; Peripheral Blood Mononuclear Cell; Plasma; Populations at Risk; Prevention; Production; Proteins; Publishing; RNA Phages; Recombinants; Research; Risk; Role; Safety; Serotyping; Serum; Small RNA; Structure; Subunit Vaccines; Testing; Tight Junctions; Vaccinated; Vaccines; Vascular Endothelial Cell; Viral; Viral Hemorrhagic Fevers; Virus; Virus Diseases; Virus-like particle; autoreactivity; base; cross reactivity; cytokine; design; efficacy testing; experimental study; high reward; high risk; immunogenic; in vivo; in vivo evaluation; infection risk; interest; mosquito-borne; mouse model; novel; novel vaccines; preclinical development; prevent; response; safety testing; vaccine candidate; vaccine safety; vector control

PROJECT SUMMARY Dengue virus (DENV) is a mosquito-borne flavivirus that infects over 390 million people worldwide annually, primarily in developing nations. There are currently no antiviral treatments for DENV and prevention efforts rely on local control of the mosquito vector, Aedes aegypti. Although efforts to develop a DENV vaccine have been pursued for over 80 years, a safe and effective vaccine remains elusive largely due to the unique pathogenic features of DENV infection. Recent concerns regarding the safety of Dengvaxia (Sanofi Pasteur) has highlighted the need for novel vaccine strategies for DENV. Recent research from several groups has implicated the viral non-structural protein 1 (NS1) in the development of vascular leakage and progression to severe disease. NS1 is produced early in infection and is secreted in large quantities from infected cells into the blood where it goes on to cause plasma leakage by disruption of endothelial cells in the vasculature, mediated through direct interaction with endothelial cells and also indirect action by eliciting immune cells to produce cytokines that cause plasma leakage. Indeed, immunization with recombinant NS1 protein or modified NS1 proteins can protect against NS1-mediated vascular leakage. However, some antibodies produced against NS1 have cross-reactivity to host proteins on endothelial cells and platelets, which are hypothesized to further contribute to pathogenesis in the host. For this reason, NS1 is a promising candidate for a DENV vaccine, but for safety reasons care should be taken to avoid eliciting potentially harmful auto-reactive antibodies. Here, we propose to use highly immunogenic bacteriophage virus-like particle (VLP) platforms to display short NS1 peptides as a novel vaccine strategy. This approach holds promise for eliciting high-titer, long-lasting antibodies against NS1 that are specific for epitopes that do not elicit dangerous cross-reactive antibodies. In Aim 1, we will engineer bacteriophage VLP-based immunogens and immunize mice to elicit antibodies. In Aim 2, we will assess the binding characteristics of antibodies elicited by our bacteriophage VLPs displaying NS1 peptides. In Aim 3, we will perform in vitro assessments of the antibodies elicited by the vaccine candidates, including their ability to block NS1-mediated endothelial cell disruption and immune-cell cytokine production. In Aim 4, we will perform an in vivo assessment of our vaccine candidates using a mouse model of dengue virus disease. Overall these studies will establish the functions of epitope-specific antibodies against NS1 and lead to the identification of vaccines against NS1 for eliciting protective and safe antibody responses.

项目摘要 登革热病毒（DENV）是一种蚊媒黄病毒，每年感染全球超过3.9亿人， 主要是在发展中国家。目前没有针对DENV的抗病毒治疗，预防工作依赖于 关于当地控制蚊子传播媒介埃及伊蚊的报告。尽管开发DENV疫苗的努力已经取得了进展， 80多年来，安全有效的疫苗仍然难以捉摸，主要是由于独特的致病性， DENV感染的特征。最近对Dengvaxia（赛诺菲巴斯德）安全性的担忧 强调了对DENV新疫苗策略的需要。几个小组最近的研究表明， 病毒非结构蛋白1（NS1）与血管渗漏的发生和进展有关， 严重的疾病。NS1在感染早期产生，并从感染的细胞大量分泌到 血液通过破坏血管系统中的内皮细胞而导致血浆泄漏， 通过与内皮细胞的直接相互作用介导，也通过引发免疫细胞的间接作用， 产生细胞因子导致血浆泄漏事实上，用重组NS1蛋白或修饰的NS1蛋白免疫， NS1蛋白可以防止NS1介导的血管渗漏。然而，产生的一些抗体 抗NS1的抗体与内皮细胞和血小板上的宿主蛋白具有交叉反应性， 进一步促进宿主的发病机制。因此，NS1是DENV的有希望的候选者。 疫苗，但出于安全原因，应注意避免引发潜在有害的自身反应， 抗体的在这里，我们建议使用高免疫原性噬菌体病毒样颗粒（VLP）平台， 展示短NS1肽作为一种新的疫苗策略。这种方法有望引发高滴度， 针对NS1的持久抗体，其特异于不会引起危险交叉反应的表位， 抗体的在目标1中，我们将工程化基于噬菌体VLP的免疫原并免疫小鼠以引发 抗体的在目标2中，我们将评估噬菌体引发的抗体的结合特征 展示NS1肽的VLP。在目标3中，我们将对由免疫抑制剂引发的抗体进行体外评估。 候选疫苗，包括它们阻断NS1介导的内皮细胞破坏和免疫细胞增殖的能力。 细胞因子产生。在目标4中，我们将使用小鼠对我们的候选疫苗进行体内评估。 登革病毒病模型。总之，这些研究将建立表位特异性抗体的功能 并导致鉴定针对NS1的疫苗以引发保护性和安全的抗体 应答